Lestat R. Ali

1.5k total citations
17 papers, 595 citations indexed

About

Lestat R. Ali is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lestat R. Ali has authored 17 papers receiving a total of 595 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Immunology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lestat R. Ali's work include Immunotherapy and Immune Responses (7 papers), CAR-T cell therapy research (6 papers) and Immune Cell Function and Interaction (6 papers). Lestat R. Ali is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), CAR-T cell therapy research (6 papers) and Immune Cell Function and Interaction (6 papers). Lestat R. Ali collaborates with scholars based in United States, Australia and United Kingdom. Lestat R. Ali's co-authors include Michael Dougan, Stephanie K. Dougan, Hidde L. Ploegh, Jessica R. Ingram, Olga Blomberg, Camilo Espinosa, Novalia Pishesha, K. Christopher García, Mohammad Rashidian and Patrick T. Bruck and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Lestat R. Ali

16 papers receiving 591 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lestat R. Ali United States 12 355 332 177 136 55 17 595
Casey Moore United States 9 315 0.9× 253 0.8× 191 1.1× 73 0.5× 53 1.0× 16 536
Aaron Y. Chang United States 13 336 0.9× 405 1.2× 249 1.4× 93 0.7× 57 1.0× 18 709
Tatiana Blanchard United States 6 380 1.1× 372 1.1× 286 1.6× 81 0.6× 70 1.3× 7 592
Kyle R. Cron United States 4 584 1.6× 299 0.9× 219 1.2× 48 0.4× 85 1.5× 10 794
Ian L. Linde United States 9 299 0.8× 220 0.7× 160 0.9× 40 0.3× 57 1.0× 11 458
Aaron T. Alpar United States 10 232 0.7× 190 0.6× 166 0.9× 53 0.4× 83 1.5× 18 454
Maria Liljefors Sweden 12 243 0.7× 224 0.7× 133 0.8× 85 0.6× 12 0.2× 20 451
Alejandro Alice United States 11 439 1.2× 440 1.3× 122 0.7× 27 0.2× 34 0.6× 18 606
Gangli An China 12 257 0.7× 340 1.0× 137 0.8× 81 0.6× 57 1.0× 24 490
Anne Mobergslien Norway 12 179 0.5× 134 0.4× 204 1.2× 124 0.9× 18 0.3× 18 480

Countries citing papers authored by Lestat R. Ali

Since Specialization
Citations

This map shows the geographic impact of Lestat R. Ali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lestat R. Ali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lestat R. Ali more than expected).

Fields of papers citing papers by Lestat R. Ali

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lestat R. Ali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lestat R. Ali. The network helps show where Lestat R. Ali may publish in the future.

Co-authorship network of co-authors of Lestat R. Ali

This figure shows the co-authorship network connecting the top 25 collaborators of Lestat R. Ali. A scholar is included among the top collaborators of Lestat R. Ali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lestat R. Ali. Lestat R. Ali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Garrido-Castro, Ana C., Noah Graham, Lestat R. Ali, et al.. (2025). Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer. Journal for ImmunoTherapy of Cancer. 13(2). e010430–e010430. 5 indexed citations
2.
Crowley, Stephanie J., Patrick T. Bruck, Max Heckler, et al.. (2023). cIAP1/2 Antagonism Induces Antigen-Specific T Cell–Dependent Immunity. The Journal of Immunology. 210(7). 991–1003. 7 indexed citations
3.
Walsh, Michael J., Lestat R. Ali, Patrick J. Lenehan, et al.. (2023). Blockade of innate inflammatory cytokines TNFα, IL-1β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression. PubMed. 3(1). ltad011–ltad011. 13 indexed citations
4.
Li, Qiang, Megan T. Hoffman, Lestat R. Ali, et al.. (2023). 798 TGFβ blockade in pancreatic cancer enhances sensitivity to combination chemotherapy. SHILAP Revista de lepidopterología. A896–A896.
5.
Walsh, Michael J., Patrick J. Lenehan, Lestat R. Ali, et al.. (2023). IFNγ is a central node of cancer immune equilibrium. Cell Reports. 42(3). 112219–112219. 13 indexed citations
6.
Li, Qiang, Megan T. Hoffman, Lestat R. Ali, et al.. (2023). Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. Gastroenterology. 165(4). 874–890.e10. 43 indexed citations
7.
Ali, Lestat R., Ana C. Garrido-Castro, Patrick J. Lenehan, et al.. (2023). PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer. The Journal of Experimental Medicine. 220(4). 17 indexed citations
8.
Quijano‐Rubio, Alfredo, Huilin Yang, Isabel Leung, et al.. (2022). A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy. Nature Biotechnology. 41(4). 532–540. 49 indexed citations
9.
Ali, Lestat R., et al.. (2021). Replicability of neural responses to speech accent is driven by study design and analytical parameters. Scientific Reports. 11(1). 4777–4777. 4 indexed citations
10.
Crowley, Stephanie J., Patrick T. Bruck, Michael J. Walsh, et al.. (2020). Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Open Biology. 10(2). 190235–190235. 11 indexed citations
11.
Fernandes, Ricardo A., Leon Su, Yoko Nishiga, et al.. (2020). Immune receptor inhibition through enforced phosphatase recruitment. Nature. 586(7831). 779–784. 78 indexed citations
12.
Clancy‐Thompson, Eleanor, Nelson M. LaMarche, Lestat R. Ali, et al.. (2019). Transnuclear mice reveal Peyer's patch iNKT cells that regulate B‐cell class switching to IgG1. The EMBO Journal. 38(14). e101260–e101260. 7 indexed citations
13.
Clancy‐Thompson, Eleanor, Paul Tyler, Lestat R. Ali, et al.. (2018). Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8+ T Cell–Effector Responses. Cancer Immunology Research. 6(12). 1524–1536. 15 indexed citations
14.
Dougan, Michael, Jessica R. Ingram, Hee‐Jin Jeong, et al.. (2018). Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs. Cancer Immunology Research. 6(4). 389–401. 71 indexed citations
15.
Ingram, Jessica R., Olga Blomberg, Mohammad Rashidian, et al.. (2018). Anti–CTLA-4 therapy requires an Fc domain for efficacy. Proceedings of the National Academy of Sciences. 115(15). 3912–3917. 125 indexed citations
16.
Clancy‐Thompson, Eleanor, Lestat R. Ali, Patrick T. Bruck, et al.. (2017). IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells. Cancer Immunology Research. 6(1). 25–35. 24 indexed citations
17.
Ingram, Jessica R., Olga Blomberg, Jonathan T. Sockolosky, et al.. (2017). Localized CD47 blockade enhances immunotherapy for murine melanoma. Proceedings of the National Academy of Sciences. 114(38). 10184–10189. 113 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Casey Moore Breakdown of academic impact, for papers by Aaron Y. Chang Breakdown of academic impact, for papers by Tatiana Blanchard Breakdown of academic impact, for papers by Kyle R. Cron Breakdown of academic impact, for papers by Ian L. Linde Breakdown of academic impact, for papers by Aaron T. Alpar Breakdown of academic impact, for papers by Maria Liljefors Breakdown of academic impact, for papers by Alejandro Alice Breakdown of academic impact, for papers by Gangli An Breakdown of academic impact, for papers by Anne Mobergslien
Rankless by CCL
2026